Development and Option Agreement by and between ACUITAS THERAPEUTICS, INC. and OMEGA THERAPEUTICS, INC. dated October 5, 2020Development and Option Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 26th, 2021 Company Industry JurisdictionTHIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), dated as of October 5, 2020 (the “Effective Date”), is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Omega and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
Development and Option Agreement by and between ACUITAS THERAPEUTICS, INC. and OMEGA THERAPEUTICS, INC. dated October 5, 2020Development and Option Agreement • July 9th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 9th, 2021 Company Industry JurisdictionTHIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), dated as of October 5, 2020 (the “Effective Date”), is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Omega and Acuitas may be referred to herein as a “Party” or together as the “Parties.”